Aldeyra Therapeutics Inc. is a biotechnology company that develops and markets medicines aimed at treating immune-mediated ocular and systemic diseases using reactive aldehyde species (RASP) modulators. Its primary product candidate for treating dry eye diseases and allergic conjunctivitis, reproxalap, is in Phase III clinical trial. The company is also developing ADX-629 and ADX-2191, clinical trial drugs for psoriasis, asthma, COVID-19, retinitis pigmentosa, primary vitreoretinal lymphoma, and the prevention of proliferative vitreoretinopathy.